<DOC>
	<DOC>NCT00348972</DOC>
	<brief_summary>To assess the safety, tolerability, and efficacy of LantusÂ® (insulin glargine) in prediabetes (IFG or IGT).</brief_summary>
	<brief_title>Lantus in Prediabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Hyperglycemia (either IGT , IFG, or untreated type 2 diabetes) HbA1c &lt; 7.0% BMI &lt; 40kg/m2 Able to perform moderate stationary bicycle exercise Chronic pharmacologic treatment for hyperglycemia, past or present CAD serum creatinine &gt; 2.0mg/dL BP &gt; 180/105 History of hypoglycemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Glargine</keyword>
	<keyword>prediabetes</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>impaired fasting glucose</keyword>
</DOC>